Get the Stockscreener App
19.29
0.42%
0.08
Pulse Biosciences Inc stock is traded at $19.29, with a volume of 120.16K.
It is up +0.42% in the last 24 hours and up +34.71% over the past month.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
See More
Previous Close:
$19.21
Open:
$19.31
24h Volume:
120.16K
Relative Volume:
0.41
Market Cap:
$1.31B
Revenue:
$-9,000
Net Income/Loss:
$-68.03M
P/E Ratio:
-18.37
EPS:
-1.05
Net Cash Flow:
$-44.76M
1W Performance:
-23.09%
1M Performance:
+34.71%
6M Performance:
+14.07%
1Y Performance:
-0.26%
1-Day Range:
$18.61
$19.63
1-Week Range:
$18.51
$24.44
52-Week Range:
$12.56
$26.30
Pulse Biosciences Inc Stock (PLSE) Company Profile
Name
Pulse Biosciences Inc
Sector
Industry
Phone
510-906-4600
Address
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
19.29 | 1.30B | -9,000 | -68.03M | -44.76M | -1.05 |
|
ISRG
Intuitive Surgical Inc
|
506.88 | 179.76B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
176.66 | 51.48B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
86.72 | 42.38B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
48.89 | 39.09B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
RMD
Resmed Inc
|
257.06 | 36.79B | 5.40B | 1.49B | 1.78B | 10.12 |
Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Initiated | Mizuho | Outperform |
| Jul-07-25 | Initiated | Oppenheimer | Outperform |
| Jul-27-21 | Initiated | Stephens | Overweight |
| Mar-11-21 | Initiated | Maxim Group | Buy |
| Jan-26-21 | Reiterated | H.C. Wainwright | Buy |
| May-12-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Feb-14-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-25-19 | Initiated | H.C. Wainwright | Buy |
View All
Pulse Biosciences Inc Stock (PLSE) Latest News
Is Pulse Biosciences (PLSE) Share Price Justified After Recent Volatility In Healthcare Sentiment - simplywall.st
ETF Watch: Will Perfect Corp Equity Warrant face regulatory challenges2025 Stock Rankings & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 20, 2026 - BioSpace
Aug EndMonth: Is Pulse Biosciences Inc benefiting from innovation trendsTrade Entry Summary & Smart Swing Trading Techniques - baoquankhu1.vn
Pulse Biosciences (NASDAQ:PLSE) Rating Increased to Hold at Wall Street Zen - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Shares Down 6.5%Here's Why - MarketBeat
Pulse Biosciences Inc (PLSE) Shares Gap Down to $22.02 on Feb 20 - GuruFocus
Oppenheimer raises Pulse Biosciences stock price target to $30 By Investing.com - Investing.com Canada
Pulse Biosciences slips despite Q4 beat after deal to sell shares - MSN
Pulse Biosciences stock slips despite Q4 beat (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference - The AI Journal
Decoding Pulse Biosciences Inc (PLSE): A Strategic SWOT Insight - GuruFocus
Pulse Biosciences Q4 2025 Earnings Call Transcript - MarketBeat
Pulse Biosciences Inc (PLSE) Q4 2025 Earnings Call Highlights: I - GuruFocus
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results - BioSpace
Pulse Biosciences Q4 Earnings Call Highlights - MarketBeat
Pulse Biosciences, Inc (PLSE) Reports Q4 Loss, Beats Revenue Estimates - Bitget
Pulse Biosciences Shares Fall After Q4 Loss Widens as Clinical Spending Rises and Revenue Remains Limited - AlphaStreet News
Pulse Biosciences to offer securities worth $200 million - marketscreener.com
Pulse Biosciences Establishes New $60 Million ATM Program - TipRanks
Pulse Biosciences (NASDAQ:PLSE) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat
Earnings Flash (PLSE) Pulse Biosciences, Inc. Reports Q4 Revenue $264K, vs. FactSet Est of $150K - marketscreener.com
PLSE: Advanced pivotal clinical programs in AF ablation with rising losses and modest initial revenue - TradingView
Pulse Biosciences Launches $59.98 Million ATM Equity Program With TD Cowen - TradingView
Pulse Biosciences Q4 Earnings Report: What Investors Need to Know - Benzinga
The Technical Signals Behind (PLSE) That Institutions Follow - Stock Traders Daily
Pulse Biosciences earnings in focus after clinical data surge By Investing.com - Investing.com South Africa
Pulse Biosciences earnings in focus after clinical data surge - Investing.com Nigeria
A Glimpse of Pulse Biosciences's Earnings Potential - Benzinga
Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock - MarketBeat
Pulse Biosciences CCO Danahy sells $1.41 million in stock By Investing.com - Investing.com Canada
Pulse Biosciences CCO Danahy sells $1.41 million in stock - Investing.com
Pulse Biosciences, Inc (PLSE) Stock Analysis: Exploring a Potential 12.99% Upside in the Healthcare Sector - DirectorsTalk Interviews
Will Pulse Biosciences Inc. stock continue dividend increases2025 Market WrapUp & Long Hold Capital Preservation Tips - mfd.ru
Is Pulse Biosciences Inc. affected by consumer sentimentTreasury Yields & Community Consensus Stock Picks - mfd.ru
Can Pulse Biosciences Inc. sustain its profitability2025 Technical Patterns & Verified Technical Trade Signals - mfd.ru
Pulse Biosciences (NASDAQ:PLSE) Shares Down 9.2% Following Insider Selling - MarketBeat
PLSE shares positive first-in-human nPulse cardiac catheter data - MSN
Pulse Biosciences (PLSE) to Release Earnings on Thursday - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Insider Kevin Patrick Danahy Sells 20,000 Shares - MarketBeat
Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 7.5%Here's What Happened - MarketBeat
Is Pulse Biosciences Inc. stock a good pick for beginners2025 Pullback Review & Consistent Income Trade Recommendations - mfd.ru
Pulse Biosciences (PLSE) Is Up 70.4% After Strong First-in-Human nPulse AF Data Release – Has The Bull Case Changed? - Sahm
Why Pulse Biosciences Inc. (6L8) stock could break out in 2025Trade Entry Report & High Win Rate Trade Alerts - mfd.ru
Pulse Biosciences, Inc. (PLSE) Stock Analysis: Riding a Wave of Innovation with a 7.39% Upside Potential - DirectorsTalk Interviews
Pulse Biosciences (NASDAQ:PLSE) Hits New 52-Week HighWhat's Next? - MarketBeat
Pulse Biosciences stock hits 52-week high at 22.76 USD By Investing.com - Investing.com South Africa
Pulse Biosciences (NASDAQ:PLSE) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Pulse Biosciences stock hits 52-week high at 22.76 USD - Investing.com
Pulse Biosciences Inc Stock (PLSE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pulse Biosciences Inc Stock (PLSE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
2.48%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):